In the US<unk>  is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C. In the EU<unk>  is indicated in adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet: * in combination with a statin in people unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe * alone in people who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone, * in people already being treated with the combination of<unk> <unk>  and ezetimibe as separate tablets with or without statin.
Bempedoic acid/ezetimibe
Ezetimibe/simvastatin
Ezetimibe/atorvastatin
Ezetimibe/rosuvastatin
Fenofibrate/simvastatin
Fenofibrate/pravastatin
Dapagliflozin/saxagliptin/metformin
Empagliflozin/linagliptin/metformin